Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory disease of the axial skeleton manifested by back pain and progressive stiffness of the spine. AS affects mostly young adults, with a peak age of onset between 20 and 30 years. 1 Pain and stiffness in the back and joints and limitation of spinal mobility reduce the ability of patients to carry out daily activities and negatively affect quality of life. AS is also associated with an increased absence from work and a higher level of work disability compared with the general population. 2 The most prevalent concerns of patients with AS are stiffness, pain and fatigue, 3 and these make up the core components of the Bath AS Disease Activity Index (BASDAI). 4 Sexual dysfunction is another important issue in patients with AS. Male patients with AS have been found to have significantly decreased sexual function, as assessed by the International Index of Erectile Function (IIEF) questionnaire and the Brief Male Sexual Function Inventory, compared with healthy controls. 5, 6 Conventional management for AS has included exercise and treatment with non-steroidal anti-inflammatory drugs. In addition, traditional disease-modifying anti-rheumatic drugs, such as methotrexate and sulfasalazine, are of benefit for peripheral arthritis in AS patients. Inhibitors of tumor necrosis factor (TNF)-a have recently been shown to significantly reduce disease activity, including pain and stiffness, as well as to improve health-related quality of life. 7 However, it is not known whether anti-TNF-a therapy also improves sexual dysfunction in AS patients. We therefore evaluated the effect of anti-TNF-a therapy on sexual dysfunction, as well as health-related quality of life and disease activity, in male patients with AS.
Materials and methods
Twenty-two married male patients 29-48 years old, who met the modified New York criteria for the diagnosis of AS, 8 were enrolled consecutively at the commencement of treatment with TNF-a blocking agents. Patients with other known medical conditions that could affect sexual function, healthrelated quality of life and/or disease activity, were excluded. No patient had a history of treatment for erectile dysfunction (ED) or a history of previous treatment with TNF-a blockers. All patients had received non-steroidal anti-inflammatory drugs and sulfasalazine for at least 3 months before the treatment with TNF-a blockers and were enrolled at the start of TNF-a blocker therapy. AS disease activity was measured using BASDAI before and after 3 months of treatment. 4 Before and after 3 months of treatment, all patients completed the Korean language version of the IIEF questionnaire, 9,10 a self-administered measure of erectile function (EF) comprising five domains: EF ( six questions with a maximum score of 30), intercourse satisfaction (IS, three questions with a maximum score of 15), orgasmic function, sexual desire and overall satisfaction (two questions each with a maximum score of 10). The IIEF is a highly sensitive and specific instrument for detecting changes in EF in response to treatment. 9 Patients with a score of 25 or less in the EF domain were considered to have ED. 5, 9 Before and after treatment, each patient also completed the RAND 36 item Health Survey 1.0, a measure of health-related quality of life, containing 36 items on the following eight scales: physical functioning, role limitations because of physical health problems, role limitations because of personal emotional problems, energy/fatigue, emotional wellbeing, social functioning, pain and general health. Each scale generates a score from 0 to 100, with a higher score indicating better health. 11 We used a Korean language version of the questionnaire. 12 The study protocol was approved by the institutional review board of the Asan Medical Center and all participants provided informed consent.
Statistical analyses were carried out using SPSS 14.0 software. The Wilcoxon signed rank test was used to analyze paired data in each individual before and after treatment. Linear regression analyses and bivariate correlation analyses (partial correlation coefficients adjusted by age) were used to assess correlations between changes in BASDAI and each domain of the IIEF.
Results
The 22 patients had a mean age of 37.8 ± 5.8 years (range, 29-48 years), and a mean BASDAI at baseline of 7.2±1.5 (range, 4.75-10). Mean disease duration was 6.3 ± 4.1 years (range, 0.6-14.2 years). Among these patients, 10 were treated with etanercept, 8 with infliximab and 4 with adalimumab. Overall, 14 of the 22 patients (63.6%) had ED at baseline, as determined by scores (p25) in the EF domain of the IIEF.
After 3 months of treatment, the mean BASDAI decreased significantly to 2.3 ± 1.5 (Po0.001). All variables of the RAND 36 item Health Survey 1.0 improved significantly after TNF-a blocker treatment. There were significant improvements in four out of the five IIEF domains (EF, Po0.001; IS, Po0.001; sexual desire, P ¼ 0.070; overall satisfaction, P ¼ 0.033) ( Table 1) . The proportion of patients with ED decreased to 45.5% after 3 months of TNF-a blocker treatment (Figure 1 ). Among 14 patients with ED, there were significant improvements in three IIEF domains (EF, P ¼ 0.006; IS, P ¼ 0.007; sexual desire, P ¼ 0.018) ( Table 2 ). Four of them (28.6%) achieved normal EF. 
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Using linear regression, we assessed whether improvement in any IIEF domain was correlated with improvement in the BASDAI. Among the five domains of IIEF, changes in IS domain were significantly associated with the changes in the BASDAI after 3 months of treatment (r 2 ¼ 0.306, P ¼ 0.008). When adjusted by age, the change in IS domain of IIEF was significantly correlated with changes in the BASDAI (partial correlation coefficient ¼ À0.484, P ¼ 0.026) ( Table 3 ).
Discussion
Sexual dysfunction is an age-related problem that has a negative effect on quality of life. 13 As AS mainly affects patients of sexually active age, sexual dysfunction in such patients is an important negative component of quality of life. Consistent with previous findings, we found that the majority of our male patients with AS had decreased sexual function and quality of life, despite being of socially and sexually active age. 5, 6 To our knowledge, no previous study has evaluated treatment-related improvements in sexual dysfunction in AS patients. Thus, our study is the first to show that anti-TNF-a therapy could improve sexual dysfunction in male AS patients. We found that 3 months of anti-TNF-a therapy significantly improved disease activity, quality of life and sexual dysfunction (including EF) in male patients with active AS. The analysis of the correlation between BASDAI and sexual function indicated that treatment-associated changes in the BASDAI may partly explain the improvements in the sexual function.
Ankylosing spondylitis is a chronic inflammatory disease, in which TNF-a acts as an important inflammatory mediator. 7 TNF-a may also have an important role in ED. For example, in patients with chronic obstructive pulmonary disease, serum TNFa concentration, a marker of systemic inflammatory status, was significantly higher in patients with moderate-to-severe ED than in those with mild to moderate ED. 14 In addition, expression of phosphodiesterase type 5, which hydrolyzes cGMP, was shown to be upregulated by nicotine and TNF-a, with the latter normalized by sildenafil, a phosphodiesterase type 5 inhibitor, suggesting that TNF-a and nicotine may blunt the pro-erectile action of nitric oxide. 15 This observational study had several limitations, including the small number of patients and the short treatment duration. As this study was designed as a pilot study to evaluate reversibility of sexual dysfunction as an important component of health-related quality of life and the effectiveness of anti-TNF-a agents on sexual dysfunction, we enrolled consecutive patients who were being treated with our routine treatment protocol for AS indicated by the National Health Insurance program of Korea. In this protocol, 3 months of treatment with sulfasalzine and non-steroidal anti-inflammatory drugs was required before the trial of an anti-TNF-a agent. Most studies investigating treatments for ED had shown some improvements in placebo arm. It is possible that placebo response affected results in this study. Absence of placebo arm was another limitation of this study. However, there were some major difference between this study and most ED trials. First, we enrolled patients with AS, regardless of their sexual function, in whom anti-TNF therapy was indicated because their disease activity was not controlled by conventional treatments. Second, patients in this study received anti-TNF agents for their AS, not for their ED. There was no known effect of anti-TNF agents on sexual function, and they were not informed about any association of their treatment (or disease) and sexual function. Thus, it is unlikely that patients expected that anti-TNF therapy for AS may improve their sexual function. We also have results that 8 male patients with AS treated with sulfasalazine and non-steroidal anti-inflammatory drugs showed no significant improvement in all IIEF domain scores although significant improvement in their disease activity after 3 months of treatments (unpublished data). These results also suggest that placebo response might not be significant in this study.
Our results also suggest that sexual dysfunction in male patients with AS may be reversed with appropriate treatment, as can other indicators of quality of life. It is not clear, however, whether the improvements in sexual function were because of improvements in disease activity and quality of life or arose from direct therapeutic effects of anti-TNF agents, which block the adverse effects of TNF-a on sexual function.
In conclusion, we have shown here that anti-TNF-a therapy significantly improved sexual dysfunction as well as disease activity (measured by BASDAI) and health-related quality of life (RAND 36 item Health Survey 1.0) in male patients with active AS. Improvements in IS domain of the IIEF was significantly correlated with improvements in BASDAI. Studies in larger numbers of patients with longer-term follow up are needed to confirm these results and to evaluate whether these responses will be maintained both during and after treatment.
